Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Sep;48(3):335–340. doi: 10.1038/bjc.1983.197

Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours.

S Coppack, E S Newlands, J Dent, H Mitchell, G Goka, K D Bagshawe
PMCID: PMC2011460  PMID: 6193801

Abstract

Serial determinations of serum alpha-foetoprotein (AFP) concentrations are well established in monitoring the response to therapy of malignant germ cell tumours. Using a radioimmunoassay (RIA) with a sensitivity down to 2kul-1 the majority (57%) of 28 patients with non-AFP producing germ cell tumours had measurable immunologically-reactive AFP in their serum while on treatment. Follow-up for 11-43 months (mean 27) without evidence of tumour activity indicated that this immunologically-reactive AFP was unlikely to be produced by tumour. In patients where the initial serum AFP was raised prior to chemotherapy the AFP concentration did not fall to the normal range at the end of the treatment in 16 (32%) of 41 patients. Follow-up of these patients for 9-48 months (mean 27) has resulted in 5 (12%) relapses in this group. Serum AFP greater than 20kul-1 three months after stopping chemotherapy was a good indicator of residual active tumour and 4 (57%) of 7 patients in this group relapsed. The production of detectable serum AFP is probably related to the type of chemotherapy used and only 7 (14%) of 51 patients treated for gestational choriocarcinoma had detectable AFP concentrations while on cytotoxic chemotherapy. The problem of interpretation of serum AFP concentration in patients with malignant germ cell tumour stresses the need to determine whether there are differences between AFP produced by germ cell tumours and that produced at other sites as a basis for a sensitive assay system able to discriminate between them.

Full text

PDF
335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagshawe K. D. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976 Sep;38(3):1373–1385. doi: 10.1002/1097-0142(197609)38:3<1373::aid-cncr2820380342>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  2. Bloomer J. R., Waldmann T. A., McIntire R., Klatskin G. Relationship of serum alpha-fetoprotein to the severity and duration of illness in patients with viral hepatitis. Gastroenterology. 1975 Feb;68(2):342–350. [PubMed] [Google Scholar]
  3. Catalona W. J. Tumor markers in testicular cancer. Urol Clin North Am. 1979 Oct;6(3):613–628. [PubMed] [Google Scholar]
  4. Elgort D. A., Abelev G. I., Levina D. M., Marienbach E. V., Martochkina G. A., Laskina A. V., Solovjeva E. A. Immunoradioautography test for alpha-fetoprotein in the differential diagnosis of germinogenic tumours of the testis and in the evaluation of effectiveness of their treatment. Int J Cancer. 1973 May;11(3):586–594. doi: 10.1002/ijc.2910110310. [DOI] [PubMed] [Google Scholar]
  5. Grigor K. M., Detre S. I., Kohn J., Neville A. M. Serum alpha1-foetoprotein levels in 153 male patients with germ cell tumours. Br J Cancer. 1977 Jan;35(1):52–58. doi: 10.1038/bjc.1977.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Javadpour N. Significance of elevated serum alphafetoprotein (AFP) in seminoma. Cancer. 1980 Apr 15;45(8):2166–2168. doi: 10.1002/1097-0142(19800415)45:8<2166::aid-cncr2820450826>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  7. Kurman R. J., Scardino P. T., McIntire K. R., Waldmann T. A., Javadpour N. Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique. Cancer. 1977 Nov;40(5):2136–2151. doi: 10.1002/1097-0142(197711)40:5<2136::aid-cncr2820400524>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  8. Masopust J., Kithier K., Rádl J., Koutecký J., Kotál L. Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int J Cancer. 1968 May 15;3(3):364–373. doi: 10.1002/ijc.2910030306. [DOI] [PubMed] [Google Scholar]
  9. McIntire K. R., Vogel C. L., Princler G. L., Patel I. R. Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma. Cancer Res. 1972 Sep;32(9):1941–1946. [PubMed] [Google Scholar]
  10. Newlands E. S., Bagshawe K. D. The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma. Cancer Chemother Pharmacol. 1982;7(2-3):211–214. doi: 10.1007/BF00254552. [DOI] [PubMed] [Google Scholar]
  11. Newlands E. S., Begent R. H., Kaye S. B., Rustin G. J., Bagshawe K. D. Chemotherapy of advanced malignant teratomas. Br J Cancer. 1980 Sep;42(3):378–391. doi: 10.1038/bjc.1980.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Newlands E. S., Begent R. H., Rustin G. J., Parker D., Bagshawe K. D. Further advances in the management of malignant teratomas of the testis and other sites. Lancet. 1983 Apr 30;1(8331):948–951. doi: 10.1016/s0140-6736(83)92079-2. [DOI] [PubMed] [Google Scholar]
  13. Norgaard-Pedersen B., Albrechtsen R., Teilum G. Serum alpha-foetoprotein as a marker for endodermal sinus tumour (yolk sac tumour) or a vitelline component of "teratocarcinoma". Acta Pathol Microbiol Scand A. 1975 Nov;83(6):573–589. doi: 10.1111/j.1699-0463.1975.tb01385.x. [DOI] [PubMed] [Google Scholar]
  14. Norgaard-Pedersen B., Axelsen N. H. Alpha-fetoprotein-like activity in sera from patients with malignant and non-malignant disease and healthy individuals. Clin Chim Acta. 1976 Sep 6;71(2):343–347. doi: 10.1016/0009-8981(76)90551-9. [DOI] [PubMed] [Google Scholar]
  15. Pearson J. C., Spaulding J. T., Friedman M. A. Testicular cancer: role of biological tumor markers. Cancer Treat Rev. 1979 Dec;6(4):217–221. doi: 10.1016/s0305-7372(79)80038-9. [DOI] [PubMed] [Google Scholar]
  16. Talerman A., van der Pompe W. B., Haije W. G., Baggerman L., Boekestein-Tjahjadi H. M. Alpha-foetoprotein and carcinoembryonic antigen in germ cell neoplasms. Br J Cancer. 1977 Mar;35(3):288–291. doi: 10.1038/bjc.1977.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Waldmann T. A., McIntire K. R. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer. 1974 Oct;34(4 Suppl):suppl–suppl:1515. doi: 10.1002/1097-0142(197410)34:8+<1510::aid-cncr2820340824>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES